Promising Antibody Breakthroughs in Cancer Treatment

Promising results from cancer trials presented at the European Society for Medical Oncology Congress show the potential of antibody-drug conjugates (ADCs) in treating advanced bladder cancer and advanced breast cancer. In a trial of ADCs for bladder cancer, the combination of enfortumab vedotin and pembrolizumab nearly doubled the median survival time compared to conventional chemotherapy. Other ADCs, such as datopotamab deruxtecan and trastuzumab deruxtecan, showed positive results in slowing tumor growth and improving survival in advanced breast cancer patients. The findings suggest that ADCs, when combined with immune-boosting drugs, could be a potent treatment option for various cancers. However, further research is needed to develop less toxic ADCs and determine safe drug combinations.